1例原发性血小板减少症合并肺血栓栓塞患者出现药物性肝损伤药学监护

doi:10.19803/j.1672-8629.2021.01.19

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (1): 90-93.
DOI: 10.19803/j.1672-8629.2021.01.19

1例原发性血小板减少症合并肺血栓栓塞患者出现药物性肝损伤药学监护

王应楷¹, 崔向丽^2,*, 刘丽宏¹

¹首都医科大学附属北京朝阳医院药事部,北京 100020;
²首都医科大学附属北京友谊医院药学部,北京 100050

收稿日期:2019-11-04 修回日期:2021-01-18 出版日期:2021-01-15 发布日期:2021-01-18
通讯作者: ^*崔向丽,女,主任药师,临床药学。E-mail:cui10@163.com
作者简介:王应楷,男,硕士,临床药学。

Pharmaceutical Care for Drug-induced Liver Injury in a Patient with Idiopathic Thrombocytopenic Purpura Complicated with Pulmonary Thromboembolism

WANG Yingkai¹, CUI Xiangli^2,*, LIU Lihong¹

¹Department of Pharmacy,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China;
²Department of Pharmacy,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China

Received:2019-11-04 Revised:2021-01-18 Online:2021-01-15 Published:2021-01-18

摘要/Abstract

摘要： 目的通过临床药师参与1例原发性血小板减少症、肺血栓栓塞、药物性肝损伤患者的治疗过程,讨论药学监护的重要性。方法临床药师协助医师对1例原发性血小板减少合并肺血栓栓塞患者进行抗凝药物的选择、剂量调整、保肝药物的选择,寻找可能导致肝损伤的药物,协助医师优化个体化治疗方案。结果患者经过治疗后,肝功能基本正常,抗凝安全有效。结论临床药师参与临床治疗中的药学监护,提高了治疗有效性,保障了患者的用药安全。

关键词: 原发性血小板减少, 肺血栓栓塞, 药物性肝损伤, 药学监护

Abstract: Objective To study the importance of pharmaceutical care through a clinical pharmacist involved in the treatment of a patient with idiopathic thrombocytopenic purpura,pulmonary thromboembolism,and drug-induced liver injury.Methods A clinical pharmacist assisted the physician in selecting an anticoagulant and its dose,adjusting the hepatoprotective drug,and identifying the drug that might have caused liver damage in a patient with primary thrombocytopenia and pulmonary thromboembolism so that the physician was able to make an individualized treatment plan.Results After treatment,the patient's liver functions basically returned to normal,and the anticoagulation medication was safe and effective.Conclusion Clinical pharmacists' participation in pharmaceutical care can improve the efficacy of medication and ensure the safety of patients.

Key words: idiopathic thrombocytopenic purpura, pulmonary thromboembolism, drug-induced liver injury, pharmaceutical care

中图分类号:

R969.3

王应楷, 崔向丽, 刘丽宏. 1例原发性血小板减少症合并肺血栓栓塞患者出现药物性肝损伤药学监护[J]. 中国药物警戒, 2021, 18(1): 90-93.

WANG Yingkai, CUI Xiangli, LIU Lihong. Pharmaceutical Care for Drug-induced Liver Injury in a Patient with Idiopathic Thrombocytopenic Purpura Complicated with Pulmonary Thromboembolism[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 90-93.

参考文献

[1] Maschmeyer G,Helweg-Larsen J,Pagano L,et al.ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients[J].J Antimicrob Chemother,2016 ,71(9):2405-2413.
[2] Lane MA,Devine ST,McDonald JR.High‐risk antimicrobial prescriptions among ambulatory patients on warfarin[J].J Clin Pharm Ther,2012 ,37(2):157-160.
[3] Anderson Jr FA,Spencer FA.Risk factors for venous thromboem-bolism[J].Circulation,2003,107(23 Suppl 1):9-16.
[4] Saleh MN,Bussel JB,Cheng G,et al.Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia:results of the long-term,open-label EXTEND study[J].Blood,2013,121(3):537-545.
[5] Kim KJ,Baek IW,Yoon CH,et al.Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies[J].Br J Haematol,2013 ,161(5):706-714.
[6] Chinese Medical Association Respiratory Diseases Pulmonary Embolism and Pulmonary Vascular Diseases Group,Chinese Medical Association Respiratory Physician Branch Pulmonary Embolism and Pulmonary Bascular Disease Working Committee,National Pulmonary Embolism and Pulmonary Vascular Disease Prevention and Treatment Group.The guideline of pulmonary thrombosis diagnosis and treatment[J].Natl Med J China(中华医学杂志),2018,98(14):1060-1087.
[7] Wei J,Jin H,Chai YF,et al.CYP2C9 and VKORC1 gene detection to guide the clinical study of individualized warfarin anticoagulation therapy in patients with acute pulmonary thromboembolism[J/OL].Chin J Crit Care Med(中华重症医学),Electron Ed,2016,9(2):91-95.
[8] Yu JJ,Kuang Y,Wang H,et al.Research status of the interaction between warfarin and antibacterial drugs and its mechanism[J].Chin J Clin Pharmacol(中国临床药理学杂志),2016,32(24):2319-2322,2336.
[9] Hosaka K,Saito S,Ishii T,et al.Safety of fondaparinux versus enoxaparin after TKA in Japanese patients[J].Orthopedics,2013,36(4):e428-e433.
[10] Gu YL,Ge WH.Yu F.Research progress on the interaction between warfarin and antibacterial drugs[J].Chin J Hosp Pharm(中国医院药学杂志),2013,33(20):1708-1710.
[11] Drug-induced liver disease group of the Chinese Society of Hepatology.Guidelines for the diagnosis and treatment of drug-induced liver injury[J].J Clin Hepatol,2017,20(2):1-18
[12] Zhang Y,You PC,Zheng QS.Investigation and analysis of 115 cases of warfarin clinical application[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2011,8(9):524-527.
[13] Zhao YQ,Gao J,Xie C.A case of pharmaceutical care of a patient with atrial fibrillation taking warfarin anticoagulant therapy[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2011,8(10):632-633.

[1]	王欣, 史磊磊, 张雨涵, 谢允东, 刘继平. 多药耐药相关蛋白转运体在药物性肝损伤中的作用研究进展[J]. 中国药物警戒, 2024, 21(2): 229-234.
[2]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[3]	詹姆斯·布坎南. 用 nR 改良海氏法则及 P_ALT 评估药物性肝损伤研究进展[J]. 中国药物警戒, 2024, 21(1): 117-120.
[4]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[5]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[6]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[7]	陈崇泽, 李婕, 旷煉, 檀学文, 刘敏惠, 刘熙, 郑燕钗, 靳洪涛. 448例住院患者药物性肝损伤相关不良反应特征分析[J]. 中国药物警戒, 2023, 20(6): 697-704.
[8]	罗琼, 李盟, 李光耀, 何彦春, 周祖山, 孙鑫, 刘成海. 635例类风湿性关节炎患者应用雷公藤制剂所致肝损伤的中医证候及联合用药特点[J]. 中国药物警戒, 2023, 20(5): 500-504.
[9]	李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510.
[10]	姚克宇, 张舒琪, 金锐, 刘丽红, 朱彦. 药物致肝损伤数据集的比较研究[J]. 中国药物警戒, 2023, 20(5): 568-573.
[11]	陈超, 朱兰, 刘丽红, 韩佳寅, 朱彦. 文献来源的补骨脂及其制剂引起药物性肝损伤特点探析[J]. 中国药物警戒, 2023, 20(4): 449-453.
[12]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[13]	王宇, 黄婧怡, 侯立新, 李爽, 崔永康, 黄兰蔚. 社区获得性肺炎患者抗生素相关性肝损伤外周血体液免疫特点分析[J]. 中国药物警戒, 2023, 20(2): 132-135.
[14]	于洁, 朱浩翔, 张继明. 疑似千里光类药物致药物性肝损伤1例分析[J]. 中国药物警戒, 2023, 20(2): 136-139.
[15]	李晓娟, 张爱武, 魏颖. 伤风停胶囊致急性药物性肝损伤1例分析[J]. 中国药物警戒, 2023, 20(2): 213-214.

1例原发性血小板减少症合并肺血栓栓塞患者出现药物性肝损伤药学监护

Pharmaceutical Care for Drug-induced Liver Injury in a Patient with Idiopathic Thrombocytopenic Purpura Complicated with Pulmonary Thromboembolism

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics